27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Moderna, Inc.'s (NASDAQ:MRNA) COVID-19 vaccine should soon find its way into India, one of the countries worst affected by the second wave of the pandemic.
What Happened: India's drug regulator, the Drugs Controller General of India, has approved the importation of Moderna's COVID-19 vaccine for restricted emergency use in India, the Hindustan Times reported, citing sources.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Permission to import Moderna's vaccine has been granted to Indian pharma company Cipla, the report said. Cipla on Monday submitted a request to the DCGI on behalf of Moderna.
Moderna had earlier communicated to the DCGI that the U.S. government has agreed to donate a certain number of its mRNA vaccines against the novel coronavirus through the COVAX alliance.
On Tuesday, Moderna released new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 Vaccine showing activity against variants of SARS-CoV-2, including the Delta variant first identified in India.
Related Link: The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Why It's Important: Moderna has gotten ahead of Pfizer, Inc. (NYSE:PFE)/BioNTech SA (NASDAQ:BNTX) in getting conditional authorization in India. India has previously authorized three vaccines: AstraZeneca plc's (NASDAQ:AZN) Covishield, Bharat Biotech's Covaxin and Russia's Sputnik.
Indications from the government point to authorization for Pfizer vaccine in the near future.
With the second wave, India became the epicenter of COVID-19 pandemic. By mid-June, India had 29.3 million reported cased of COVID-19 infection, with the death toll at 367,081.
MRNA Price Action: Moderna shares were up 6.21% at $236.78 at last check Tuesday.
Related Link: Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.